Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
In this week’s Pathways Picks: UK charts its AI regulatory course; FDA works on mental health generative AI guidance; transcatheter mitral valve devices selected as the first to undergo EU Joint Clinical Assessments, and get CPT code upgrades; South Korea streamlines Class II review process; FDA plans notice to “improve representation” in clinical trials; and more updates.
Coronary microvascular disease can contribute to major cardiovascular pathology, but there are no approved disease-modifying therapies. On the hunt for a new solution, VahatiCor is pursuing a new device that narrows coronary sinus flow to improve perfusion in the microvascular network.
Medtech investing has maintained its momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook. Excerpted from our recent feature, “As Dollars Chase AI Dream, Investors Stay Grounded.”